[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,902,856
  • Shares Outstanding, K 231,773
  • Annual Sales, $ 510,170 K
  • Annual Income, $ 146,930 K
  • EBIT $ 215 M
  • EBITDA $ 224 M
  • 60-Month Beta 0.72
  • Price/Sales 3.78
  • Price/Cash Flow 12.96
  • Price/Book 5.05

Options Overview Details

View History
  • Implied Volatility 61.84% (+5.77%)
  • Historical Volatility 62.14%
  • IV Percentile 46%
  • IV Rank 20.68%
  • IV High 147.60% on 03/27/26
  • IV Low 39.48% on 01/22/26
  • Expected Move (DTE 5) 0.62 (7.56%)
  • Put/Call Vol Ratio 0.82
  • Today's Volume 209
  • Volume Avg (30-Day) 835
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 106,286
  • Open Int (30-Day) 108,297
  • Expected Range 7.59 to 8.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.16
  • Number of Estimates 1
  • High Estimate $0.16
  • Low Estimate $0.16
  • Prior Year $0.15
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.45 +10.20%
on 06/02/26
8.90 -7.70%
on 06/10/26
-0.20 (-2.38%)
since 05/12/26
3-Month
7.21 +13.87%
on 03/26/26
16.39 -49.89%
on 03/17/26
-6.78 (-45.23%)
since 03/12/26
52-Week
7.21 +13.87%
on 03/26/26
21.53 -61.87%
on 06/13/25
-13.39 (-61.99%)
since 06/12/25

Most Recent Stories

More News
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

NEW ORLEANS , June 12, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications...

ADMA : 8.21 (-1.32%)
ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August...

ADMA : 8.21 (-1.32%)
ADMA Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against ADMA Biologics, Inc.

SAN DIEGO , June 12, 2026 /PRNewswire/ -- Robbins LLP  informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc....

ADMA : 8.21 (-1.32%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 12, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors...

ADMA : 8.21 (-1.32%)
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or...

ADMA : 8.21 (-1.32%)
Law Offices of Frank R. Cruz Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”)...

ADMA : 8.21 (-1.32%)
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. (“ADMA” or “the Company”) (NASDAQ: ADMA...

ADMA : 8.21 (-1.32%)
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK , June 11, 2026 /PRNewswire/ --

ADMA : 8.21 (-1.32%)
INVESTOR ALERT: Securities Class Action Filed Against ADMA Biologics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA)...

ADMA : 8.21 (-1.32%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti , LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. (“ADMA” or the “Company”)...

ADMA : 8.21 (-1.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 8.55
2nd Resistance Point 8.46
1st Resistance Point 8.34
Last Price 8.21
1st Support Level 8.13
2nd Support Level 8.04
3rd Support Level 7.92

See More

52-Week High 21.53
Fibonacci 61.8% 16.06
Fibonacci 50% 14.37
Fibonacci 38.2% 12.68
Last Price 8.21
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.